Resumo

ALVA-ARROYO, NANCY VERÓNICA; HERNANDEZ-SANCHEZ, NANCY; GASCA-ALDAMA, JOSÉ CARLOS  e  SALVADOR-IBARRA, IBZAN. COVID-19 and mortality in patients with systemic lupus erythematosus. Acta Med Colomb [online]. 2022, vol.47, n.4, pp.39-42.  Epub 27-Maio-2023. ISSN 0120-2448.  https://doi.org/10.36104/amc.2022.2551.

In december 2019, a new disease erupted in Wuhan, China, caused by coronavirus 2019 (CO-VID-19), which produces severe acute respiratory syndrome (SARS-CoV-2).

Some cases associate COVID-19 with autoimmune disorders; the role of this virus in autoimmunity is poorly understood. Systemic lupus erythematosus (SLE) is an autoimmune disorder. Baricitinib is a Janus kinase inhibitor (JAK) approved for the treatment of autoimmune and inflam matory disorders, recently used for treating severe COVID-19 disease.

We discuss four cases of SLE with COVID-19, two of whom were admitted to the intensive care unit and died, with a history of lupus nephritis; the following two cases survived. The risk fac tors which increase mortality in SLE are not yet known; however, lupus nephritis was associated with COVID-19 mortality. More studies are needed to understand the risk between autoimmune disorders and COVID-19. (Acta Med Colomb 2022; 47. DOI:https://doi.org/10.36104/amc.2022.2551).

Palavras-chave : SARS-CoV-2; SLE; baricitinib; mortality; steroids.

        · resumo em Espanhol     · texto em Inglês | Espanhol     · Inglês ( pdf ) | Espanhol ( pdf )